Symbol="IMRN"
AssetType="Common Stock"
Name="Immuron Ltd ADR"
Description="Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia."
CIK="1660046"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="62 LYGON STREET, LEVEL 3, CARLTON, VICTORIA, AU"
FiscalYearEnd="June"
LatestQuarter="2022-06-30"
MarketCapitalization="11788600"
EBITDA="-3072019"
PERatio="None"
PEGRatio="0"
BookValue="3.72"
DividendPerShare="0"
DividendYield="0"
EPS="-0.36"
RevenuePerShareTTM="0.2"
ProfitMargin="-2.703"
OperatingMarginTTM="-2.752"
ReturnOnAssetsTTM="-0.0793"
ReturnOnEquityTTM="-0.133"
RevenueTTM="1117900"
GrossProfitTTM="523500"
DilutedEPSTTM="-0.36"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.527"
AnalystTargetPrice="6.41"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="15.44"
PriceToBookRatio="0.738"
EVToRevenue="0.413"
EVToEBITDA="0.888"
Beta="1.268"
num_52WeekHigh="3.21"
num_52WeekLow="1.39"
num_50DayMovingAverage="1.989"
num_200DayMovingAverage="2.02"
SharesOutstanding="5695000"
DividendDate="None"
ExDividendDate="None"
symbol="IMRN"
open="1.95"
high="1.99"
low="1.94"
price="1.94"
volume="1280.00"
latest_trading_day="2023-08-10"
previous_close="2.07"
change="-0.13"
change_percent="-6.2802%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="17"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="83"
Volume_recent_avg="229772"
Change_recent_avg="0.01"
Delta_recent_avg="0.17"
Variance_recent_avg="0.08"
Change_ratio_recent_avg="0.13"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="83"
Aroon_momentum_negative="17"
image_negative_thumbnail_id_1="106"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0070.jpeg"
image_negative_thumbnail_id_2="93"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0083.jpeg"
image_neutral_thumbnail_id_1="533"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0066.jpeg"
image_neutral_thumbnail_id_2="587"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0012.jpeg"
image_positive_thumbnail_id_1="963"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0125.jpeg"
image_positive_thumbnail_id_2="1000"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0162.jpeg"
image_professor_thumbnail_id_1="1174"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
image_professor_thumbnail_id_2="1190"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0024.jpeg"
